Loading patent…
AssigneeCiba Corning Diagnostics Corp.
InventorsJeanne P. Harvey, Victoria A. Crebbin, Roger P. Walker, Victor Liu, Susan L. Hammond, Patricia A. McDonald
Estimating the term…
Diagnostic/prognostic methods are provided for detecting and/or quantitating in the body fluids, preferably serum, of mammals carrying a malignant tumor burden, elevated levels of a portion of the epidermal growth factor receptor (EGFr) which comprises substantially the EGFr ectodomain having a molecular weight in the range of from about 90 kilodaltons (kd) to about 115 kd, preferably from about 95 kd to about 105 kd, and more preferably about 100 kd. Substantially pure compositions comprising said EGFr ectodoman protein and/or fragments thereof are disclosed as well as test kits for performing the disclosed assays.
A diagnostic/prognostic method for sguamous cell carcinoma or urinary tract cancer comprising detecting and/or guantitating in a mammalian urine or bladder wash sample a portion of the epidermal growth factor (EGFr) which comprises substantially the EGFr ectodomain and which has a molecular weight in the range of from about 90 kilodaltons (kd) to about 115 kd, wherein an elevated concentration of said portion above the concentration for healthy mammals or for those with benign disease indicates the presence of squamous cell carcinoma or uninary tract cancer.
A diagnostic/prognostic method for detecting squamous cell carcinoma or urinary tract cancer in a patient which comprises:
Dependencies are inferred from the claim text.